Anavar 50 - Pharmaqo Labs

Oxandrolone was introduced as Anavar by Searle in the early 1960s, with a profile emphasizing low androgenicity and zero estrogenic activity. Originally used for burns, infections, and muscle loss, it became known for preserving lean mass with minimal side effects. Marketed in both the U.S. and Netherlands, Anavar was pulled in 1989. Bio-Technology General acquired the rights and relaunched it in 1995 as Oxandrin, targeting serious catabolic conditions under FDA orphan-drug status.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Anavar 50 by Pharmaqo Labs, consult with your doctor or healthcare professional.